Vancouver, British Columbia – (November 5th, 2018) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX, FSE: 20B, OTCQB: BMKDF) is pleased to announce that Dr. Myron Weisfeldt will be joining BioMark’s Scientific Advisory Team.
Mr. Rashid Ahmed, CEO and President of BioMark Diagnostics says: “We are extremely proud and honored to have Dr. Myron Weisfeldt join our scientific board. Over the past few months Dr. Weisfeldt provided BioMark with excellent counsel on how to fine tune our lung cancer clinical trial protocols and opened potential new opportunities for collaboration. This is what we at BioMark need as we transition into a fully commercial entity.”
BioMark’s board and shareholders welcome Dr. Weisfeldt and look forward to his professional contribution to building BioMark into a stronger international entity.
About Dr. Myron Weisfeldt
Dr. Myron Weisfeldt is the Senior Medical Director of Johns Hopkins Technology Ventures. In this position he provides advice on strategies and evaluation of intellectual property of Johns Hopkins to faculty. He is also University Distinguished Service Professor. From 2001 to 2014 Dr. Weisfeldt was the William Osler Professor of Medicine and Chairman of the Department of Medicine at Johns Hopkins School of Medicine. He was also Physician-in-Chief of the Johns Hopkins Hospital. Dr. Weisfeldt received a BA and MD from the Johns Hopkins University. He trained in Cardiology at the Massachusetts General Hospital and the National Institutes of Health and from 1975 to 1991, was Director of the Cardiology Division at the Johns Hopkins. From 1991 to 2001, he was Chairman of the Department of Medicine and Samuel Bard Professor of Medicine at the Columbia University College of Physicians and Surgeons and Director of the Medical Service at the Columbia-Presbyterian Campus of the New York Presbyterian Hospital. Dr. Weisfeldt was Chairman of the Cardiology Advisory Board of the National Heart Lung and Blood Institute from 1987 to 1990 and held the position of President of the American Heart Association in 1990. He is a member of the National Academy of Medicine.
His research interests have included heart function, age changes in the heart and circulation, and cardiopulmonary resuscitation. Since 2003 he has been study chair for a large-scale ongoing clinical trials network to conduct randomized definitive trials of devices, drugs and other therapies for out-of-hospital cardiac arrest and severe traumatic injury sponsored by NHLBI and others. This network is called Resuscitation Outcomes Consortium and is now on no cost extension.